ArticleAntimicrobial agents and chemotherapy2001
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Article in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 143 citations in OpenAlex.
- Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.Clinical pharmacokinetics · 2011Trial
- Skin concentrations and pharmacokinetics of posaconazole after oral administration.Antimicrobial agents and chemotherapy · 2010Trial
- Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Antimicrobial agents and chemotherapy · 2007Trial
- Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.Antimicrobial agents and chemotherapy · 2006Trial
- Disposition of posaconazole following single-dose oral administration in healthy subjects.Antimicrobial agents and chemotherapy · 2004Trial
- Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men.Antimicrobial agents and chemotherapy · 2004Trial
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.British journal of clinical pharmacology · 2004Trial
- Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.Antimicrobial agents and chemotherapy · 2003Trial
- Comparing Efficacy and Safety of Itraconazole Solution Versus Posaconazole for Antifungal Prophylaxis After Heart Transplant.Open forum infectious diseases · 2026Article
- A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- The Specific Binding and Promotion Effect of Azoles on Human Aldo-Keto Reductase 7A2.Metabolites · 2023Article
- Article
- NewRSC advances · 2019Article
- An update on the application of nano-scaled carriers against fluconazole-resistantCurrent medical mycology · 2019Article
- Synthesis, characterization, and in vitro activity againstNanotechnology, science and applications · 2017Article
- Posaconazole: An Update of Its Clinical Use.Pharmacy (Basel, Switzerland) · 2015Review
- Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.Antimicrobial agents and chemotherapy · 2015Article
- Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group.Drug design, development and therapy · 2015Article
- Triazole derivatives with improved in vitro antifungal activity over azole drugs.Drug design, development and therapy · 2014Article
- Anti-fungal resistance in candida isolated from oral and diaper rash candidiasis in neonates.Bioinformation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all Candida spp. (MIC at which 90% of the isolates were inhibited [MIC(90)], 0.5 microg/ml; 97% of MICs were < or =1 microg/ml) and C. neoformans (MIC(90), 0.5 microg/ml; 100% of MICs were < or =1 microg/ml). Candida albicans was the most susceptible species of Candida (MIC(90), 0.06 microg/ml), and Candida glabrata was the least susceptible (MIC(90), 4 microg/ml). Posaconazole was more active than itraconazole and fluconazole against all Candida spp. and C. neoformans. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.